Latest News
All Times Eastern
- My wife wants us to spend $5,000 to attend her cousin’s destination wedding. I don’t want to go. Am I being selfish?
- ‘I feel used’: My partner stays with me 5 nights a week, even though he owns his own home. Should he pay for utilities and food?
- DeSantis promises to make America Florida. But Florida isn’t Florida anymore, critics say.
- Special counsel Durham to testify before House committee on June 20 about his investigate-the-investigators report
- From solemn reflection to ‘three-day hootenanny’: the evolution, and degradation, of the Memorial Day holiday
- How much does a mammogram cost? That depends on whether it’s ‘diagnostic’ or ‘screening.’
- How Joe Biden and Kevin McCarthy got to yes on their debt-ceiling compromise
- Global stock markets breathe a sigh of relief over Biden-McCarthy pact to avert U.S. debt default
- ‘He’s content living paycheck to paycheck’: My husband won’t work or get a driver’s license. Now things have gotten even worse.
- Don’t get stung by buy-now- pay-later services: ‘It is kind of a recipe for disaster if not managed carefully’
to be replaced
Oncolytics Biotech Inc.
ONCYUS
$
0.03
1.71%
After Hours
$
1.7800
After Hours Volume:
5.84K
| Close | Chg | Chg % |
|---|---|---|
| $1.7500 | -0.4100 | -18.98% |
Volume: 1.3M
65 Day Avg: 215.15K
1.7303
Day Range
2.1400
0.8021
52 Week Range
2.2800
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
ONCY Overview
Key Data
- Open $2.1400
- Day Range 1.7303 - 2.1400
- 52 Week Range 0.8021 - 2.2800
- Market Cap $110.87M
- Shares Outstanding 64.09M
- Public Float 63.24M
- Beta 1.31
- Rev. per Employee N/A
- P/E Ratio N/A
- EPS -$0.3092
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 159.38K 05/15/23
- % of Float Shorted 0.25%
- Average Volume 215.15K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 7
Full Ratings
Recent News
Oncolytics prices offering at 14% discount
Oncolytics Biotech Inc.'s (ONCY, ONC.T) offer of eight million shares priced at a 14% discount to Tuesday's close. The Calgary-based drug developer's shares were halted in premarket trading as the company disclosed the off...
Canada hot stocks : Oncolytics, Just Energy
Among the companies whose shares are making notable moves in Friday's session are Oncolytics Biotech Inc. ONCY, Just Energy Group Inc. JE.T and Southern Pacific Resource Corp. STP.T. Oncolytics (C$4.68, up 31%) said result...
Oncolytics shares up on positive Reolysin results
Oncolytics Biotech Inc. (ONCY, ONC.T) said results were positive from a mid-stage U.S. trial examining the use of its lead product candidate Reolysin in helping shrink tumors. Shares soared 41% to $5.05 in recent premarket...
Oncolytics rises 27% after positive Phase III data
NEW YORK (MarketWatch) -- Oncolytics Biotech Inc. jumped 22% in premarket trades on Thursday after the company announced positive top line data for the first endpoint in a randomized Phase III study of its Reolysin drug f...
Oncolytics Biotech up 27% in premarket
Premium Starting a new bull trend?
CHICAGO (CBS.MW) -- After two months of trending lower, the corrective bounce that started may have transitioned to a full blown uptrend.
Premium Is this bounce sustainable?
CHICAGO (CBS.MW) -- The pre-market bias is lower Tuesday behind modest losses in European and Asian markets.
Premium Nasdaq may have found a near-term bottom
CHICAGO (CBS.MW) -- Stocks posted a positive open Tuesday behind modest gains in European markets.
Expert Ratings for Oncolytics Biotech
on Benzinga.com
Oncolytics Biotech (ONCY) Receives a Buy from H.C. Wainwright
on TipRanks.com
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023
on Benzinga.com
Oncolytics Biotech: Q1 Earnings Insights
on Benzinga.com
Earnings Scheduled For May 5, 2023
on Benzinga.com
Oncolytics Biotech's Earnings: A Preview
on Benzinga.com
FDA’s Wave of Fast Track Designations Pushing Momentum in Healthcare Sector in 2023
USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when ...
on Baystreet.ca
Biotech Sector Delivering Increased Optimism in Battle Against Pancreatic Cancer
USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the ...
on Baystreet.ca
Breast Cancer Treatment Options Evolved Over the Last 12 Months, Bringing More Hope for 2023
USA News Group – Treatments for various forms of breast cancer continue to evolve, with several ...
on Baystreet.ca
Maxim Group Keeps Their Buy Rating on Oncolytics Biotech (ONCY)
on TipRanks.com
Earnings Scheduled For March 3, 2023
on Benzinga.com
Oncolytics Biotech's Earnings: A Preview
on Benzinga.com
New Strong Buy Stocks for January 18th
on Zacks.com
Oncolytics Biotech Inc.
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.